None
Quote | OSE Immunotherapeutics SA (OTCMKTS:ORPOF)
Last: | $ |
---|---|
Change Percent: | 0.00% |
Open: | $N/A |
Close: | $4.00 |
High: | $N/A |
Low: | $N/A |
Volume: | 0 |
Last Trade Date Time: | 02/12/2020 04:41:07 pm |
News | OSE Immunotherapeutics SA (OTCMKTS:ORPOF)
OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective NANTES, France, April 16, 2024 – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, to...
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology Nantes, France – April 2, 2024 – 7:30 am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) to...
Message Board Posts | OSE Immunotherapeutics SA (OTCMKTS:ORPOF)
Subject | By | Source | When |
---|---|---|---|
ORPOF: inactive security. FINRA deleted symbol: | Renee | investorshub | 12/27/2022 10:13:32 PM |
OSE Immunotherapeutics Announces Dosing of the First Healthy | Bandicoot_Inv | investorshub | 05/26/2021 8:41:46 AM |
https://www.globenewswire.com/news-release/2021/05/26/2236023/0/en/OSE-Immunothe | Bandicoot_Inv | investorshub | 05/26/2021 8:40:58 AM |
News, Short Squeeze, Breakout and More Instantly...
OSE Immunotherapeutics SA Company Name:
ORPOF Stock Symbol:
OTCMKTS Market:
OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective NANTES, France, April 16, 2024 – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, to...
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology Nantes, France – April 2, 2024 – 7:30 am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) to...
Financial highlights €18.7 million available cash as of December 31 st , 2023, not including the upcoming $48 million payment as part of the recent collaboration and license partnership (February 2024) with AbbVie 1 , nor the €5.8 million of R&D Tax credit, p...